Zafgen announced two late-breaking abstracts were accepted for poster presentations at the upcoming American Diabetes Association 77th Scientific Sessions being held in San Diego from June 9-13, 2017. The clinical abstract titled, “Single and Multiple Dose Evaluation of a Novel MetAP2 Inhibitor: Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial,” will include the full data set from the Phase 1 clinical trial of ZGN-1061, the Company’s second generation MetAP2 inhibitor. The Company will also present a preclinical abstract titled, “The MetAP2 Inhibitor ZGN-1061 Improves Glycemia and Has Weight Loss Efficacy with an Improved Safety Profile in Preclinical Models.”
Poster Presentations:
Poster Number: 144-LB
Title: Single and Multiple Dose Evaluation of a Novel MetAP2 Inhibitor: Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Category: 12-D Clinical Therapeutics/New Technology—Non-Insulin Injectables
Late-Breaking Poster Session: Sunday, June 11, 2017, 12-1pm PDT
Poster Number: 143-LB
Title: The MetAP2 Inhibitor ZGN-1061 Improves Glycemia and Has Weight Loss Efficacy with an Improved Safety Profile in Preclinical Models
Category: 12-D Clinical Therapeutics/New Technology—Non-Insulin Injectables
Late-Breaking Poster Session: Sunday, June 11, 2017, 12-1pm PDT
About ZGN-1061
ZGN-1061 is a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor that was advanced into development due to its unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In pre-clinical studies, ZGN-1061 has demonstrated promising efficacy in animal models of type 2 diabetes and obesity, with an improved pharmacokinetic profile and safety margin relative to previous molecules in the MetAP2 class. As demonstrated clinically for MetAP2 inhibitors, ZGN-1061 is anticipated to improve glycemic control while also helping to restore balance to fat metabolism, enabling calories to once again be used as a productive energy source, leading to improved metabolic control and long-term weight loss. Zafgen recently completed its first Phase 1 clinical trial of ZGN-1061, and is planning to advance the compound to Phase 2 clinical testing in patients with type 2 diabetes who are overweight or obese. Zafgen holds exclusive worldwide rights for the development and commercialization of ZGN-1061.
Filed Under: Drug Discovery
